Clinical trials: Natural Killer Cell Malignancies
Metastatic Breast Cancer
Implication of CCR4-NOT Complex Subunit 7 Expression in Natural Killer Cell Resistance in Metastatic Breast Cancer
Being a mechanistic study, this work aims to figure out "the role of the cytoplasmic mRNA deadenylase CNOT7 expressed protein on NK cell resistance in metastatic BC".
- Trial name
- CCR4-NOT (NCT06320392)
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Ain Shams University
Chronic Myeloproliferative Disorders, Leukemia
Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen
RATIONALE: Giving chemotherapy, such as fludarabine and busulfan, before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- LCCC0510 (NCT00448357)
- Testing
- rabbit anti-thymocyte globulin (ATG), therapeutic allogeneic lymphocytes, busulfan
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
This study is a Phase II, single arm, open label multicenter trial designed to investigate the use of haploidentical donor derived NK cells (K-NK002) for the treatment of patients with high-risk acute myeloid leukemia (AML) or…
- Trial name
- NCT04395092
- Testing
- K-NK002, Conditioning Regimen, HaploBMT
- Where
- 2 sites in United States
- Sponsor
- Kiadis Pharma
Allogeneic Stem Cell Transplant Recipient, Blasts 10 Percent or More of Bone Marrow Nucleated Cells
Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML
This phase I trial studies the side effects of donor natural killer (NK) cell therapy in treating patients with acute myeloid leukemia that has come back (recurrent) or has not responded to treatment (refractory).
- Conditions
- Allogeneic Stem Cell Transplant Recipient, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT04220684
- Testing
- Cytarabine Hydrochloride, Fludarabine, Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Sumithira Vasu
Pain, Anesthesia
Effects of Anesthetic Technique on NK Cells
The proposed study is a pilot prospective, single-blinded, randomized controlled trial evaluating the effects of two routine, standard-of-care, anesthetic techniques on natural killer cell population size and cytotoxicity in…
- Conditions
- Pain, Anesthesia, Cancer
- Trial name
- NCT02669186
- Testing
- Bupivacaine + Fentanyl, Bupivacaine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Non-small Cell Lung Cancer
CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)
Non - small cell lung cancer ( NSCLC ) accounts for more than 80% of lung cancer. The main treatment for early stage patients is surgical resection, but about 30% -70% patients will relapse.
- Trial name
- NCT01533727
- Testing
- Autologous CIK Transfusion plus Chemotherapy, chemotherapy alone
- Where
- China
- Sponsor
- Sun Yat-sen University
Multiple Myeloma
UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma
The purpose of this study is to determine the therapeutic efficacy of the exp-NK cell therapy in research participants with relapsed high risk MM [defined as gene expression profile (GEP) 70 gene score ≥0.66 and/or metaphase…
- Trial name
- NK2010-35 (NCT01313897)
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Natural Killer/T-cell Lymphoma, Relapsed Natural Killer/T-cell Lymphoma
Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy
This study is to analyze the efficacy of PD1 inhibitor and anti-CD38 antibody in relapsed or refractory NK/T-cell lymphoid malignancy.
- Conditions
- Natural Killer/T-cell Lymphoma, Relapsed Natural Killer/T-cell Lymphoma, Refractory Natural Killer/T-cell Lymphoma
- Trial name
- ICING (NCT04763616)
- Testing
- Isatuximab, Cemiplimab
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Won Seog Kim
B2 Thymoma, Thymic Carcinoma
Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
This Phase 1/2 study evaluates the safety, tolerability, and preliminary efficacy of target-selected CAR-natural killer (CAR-NK) cells in adults with relapsed or refractory B2 thymoma or thymic carcinoma.
- Trial name
- SELECT-NK-THYM (NCT07598955)
- Testing
- Cyclophosphamide, Fludarabine, EB-CAR30-NK
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Cortisol Excess, Stress, Psychological
Effects of "Vitamin N" Nature Immersion Therapy on Stress Levels in Health Care Workers in the City of Bogotá
Recent studies on health personnel in Colombia have evidenced the considerable increase in the levels of stress and anxiety, among other psychological disorders, as a product of the COVID-19 pandemic that is being experienced…
- Conditions
- Cortisol Excess, Stress, Psychological, Anxiety, Epigenetic Disorder
- Trial name
- NCT05315388
- Testing
- Immersion therapy in nature - Vitamin N
- Where
- Colombia
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Jeadran N. Malagón-Rojas
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation
The protocol treatment is to evaluate clinical effects of donor-derived natural killer cells that are given after HLA-mismatched hematopoietic cell transplantation.
- Trial name
- DNKI-II (NCT01795378)
- Testing
- donor natural killer cell infusion
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Asan Medical Center
Diffuse Large B-cell Lymphoma
Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients
Primary objective: To compare the event free survival for 3years of R-CHOP plus Biocell Natural Killer Cell to R-CHOP therapy with DLBCL patients.
- Trial name
- NKCell (NCT00846157)
- Testing
- NKM injection
- Where
- South Korea
- Volunteers
- 276 people
- Sponsor
- NKBio Co.Ltd.
Cancer, Chronic Stress
Can You Breathe Your Way To Better Health?
The purpose of this clinical trial is to explore the effects of either a 2-week high-intensity interval training (HIIT) or breath training intervention on measures of overall health, circulating biomarkers of stress, and immune…
- Conditions
- Cancer, Chronic Stress, Autonomic Dysfunction
- Trial name
- NCT06829836
- Testing
- Hight intensity interval training, Cyclic Hyperventilation with Retention
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Northern Colorado
Glioblastoma Multiforme
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
A Phase 1b/2, Multicenter, Open-Label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)
- Trial name
- NCT02586857
- Testing
- ACP-196
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Acerta Pharma BV
Melanoma
High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma
The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of melanoma.
- Trial name
- NCT03007823
- Testing
- High-activity natural killer
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Acute Myeloid Leukemia
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia
The purpose of this study is to assess the feasibility and efficacy of a novel form of therapy-haploidentical NK cell transplantation-in patients with standard-risk AML.
- Trial name
- NCT00703820
- Testing
- Cytarabine, Daunorubicin, Etoposide
- Where
- 8 sites in United States, Singapore
- Volunteers
- 324 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Myeloid Leukaemia
A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia
This is a single group, Phase 1, single-arm, dose escalation study to determine the candidate dose(s), and evaluate safety, tolerability, and preliminary anti-tumor activity of SAR445419 administered after fludarabine and…
- Trial name
- NCT05712278
- Testing
- SAR445419, fludarabine, cytarabine
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Sanofi
Minimal Residual Disease
Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease
This is an open-label, Phase I study of QN-030a (allogeneic NK cell therapy) in Acute Myeloid Leukemia Minimal Residual Disease(AML MRD).
- Trial name
- NCT05601830
- Testing
- QN-030a, Cyclophosphamid, Fludarabine
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Non-small Cell Lung Cancer Metastatic, First-line Treatment
Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer
This prospective, multi-center, open-label, phase II, randomized controlled trial (CCICC-002b) is to evaluate the efficacy and safety of autologous cytokine-induced killer cell immunotherapy in combination with PD-1 inhibitor and…
- Trial name
- CCICC-002b (NCT04836728)
- Testing
- CIK cells injection, Sintilimab Injection, Pemetrexed
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Nasal and Nasal-type NK/T-cell Lymphoma
Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ
The purpose of this study is to evaluate the efficacy and safety of DDGP regiment (gemcitabine，pegaspargase,cisplatin,dexamethasone) for patients with stage Ⅲ/Ⅳ Natural Killer (NK)/T Cell Lymphoma.
- Trial name
- CTTNKTL-Ⅲ/Ⅳ (NCT01501149)
- Testing
- DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase), Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Mingzhi Zhang